The first full day of SLAS2023 offered plenty for visitors to see and learn from. Here are some of the biggest launches that were on offer throughout day one of the show. PerkinElmer targets screening methods End-to-end solutions provider PerkinElmer launched two new products at the show targeting both high high-throughput screening (HTS) applications and […]

Gary Connors, Partner at business consulting company Oliver Wight EAME looks at some of the most important factors that will affect the pharmaceutical industry going forward.   We advise all our clients to make assumptions and think about scenarios that could affect their business at least five years in advance. I’m not a futurist, neither […]

DDW Editor Reece Armstrong takes a look at the pharmaceutical research and development market in 2023 and asks key opinion leaders what challenges and trends will emerge throughout the year.   The Market After over two years of the Covid-19 pandemic, 2022 year was somewhat of a return to normal for both the world at […]

The DDW SLAS2023 supplement is out now.  Ahead of SLAS2023 which takes place 25 February – 1 March, the supplement explores the innovations and technologies that are driving drug discovery and laboratory research.  The DDW SLAS2023 supplement looks towards the event and covers key topics including:      Acquiring deeper insights and acceleration with AI   Connecting lab […]

Kevin Hemphill, R&D Manager at PerkinElmer’s Horizon Discovery explores how base editing has emerged as an attractive gene editing option for researchers wanting to develop stem cell-based therapies.   Increasing interest in CRISPR-Cas gene editing systems over recent years has delivered innovative developments in precision genome engineering technologies, holding enormous potential for applications across the healthcare […]

Research into antibiotic-resistant priority pathogens has boomed in the five years since the World Health Organisation (WHO) released a list of 12 families of bacteria that desperately need new antibiotics.  Data from Elseveir’s Scopus database show that since 2017, 227,808 papers have been published on the 12 pathogens. The WHO released a list of bacteria […]

World Antimicrobial Awareness Week highlights the fact that antimicrobials have formed the bedrock of modern medicine, making surgeries, cancer care and treatments for life-threatening infections possible and improving human health in the process.  For years now, experts have laboured against the rise of antimicrobial resistance (AMR), urging governments to put in place policies that promote […]

Seven pharmaceutical companies have announced a joint initiative to reduce near-term emissions and help develop net zero health systems.   CEOs from AstraZeneca, GSK, Merck KGaA, Novo Nordisk, Roche, Samsung Biologics and Sanofi announced commitments to tackle climate change through the Sustainable Markets Initiative (SMI) Health Systems Task Force, a public-private partnership launched last year at […]

Michael Frisby, Partner at Stevens & Bolton LLP, examines where legal disputes are likely to occur within the pharmaceutical industry.  The current economic environment has fuelled fears of recession and with it a rise in disputes. But where are disputes likely to arise for life sciences businesses and what can be done?  Issues within the […]

GSK has announced strong quarterly results, reporting sales of £7.8 billion and growth in various sectors of the business.   Overall, the company’s adjusted operating profit for the third quarter came in at £2.6 billion, a 17% increase compared to the same period last year and reflecting a 4% year-on-growth at CER.   The quarterly results are […]